| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Indaptus Therapeutics Inc. Common Stock (NASDAQ: INDP)
INDP Technical Analysis
5
| As on 9th Jun 2023 INDP STOCK Price closed @ 2.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.30 & Strong Sell for SHORT-TERM with Stoploss of 5.17 we also expect STOCK to react on Following IMPORTANT LEVELS. |
INDPSTOCK Price
| Open | 2.08 | Change | Price | % |
| High | 2.08 | 1 Day | -0.09 | -4.29 |
| Low | 1.99 | 1 Week | 0.41 | 25.62 |
| Close | 2.01 | 1 Month | -0.62 | -23.57 |
| Volume | 7500 | 1 Year | -4.33 | -68.30 |
| 52 Week High 6.34 | 52 Week Low 1.37 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| INDP Daily Charts |
INDP Intraday Charts |
Whats New @ Bazaartrend |
INDP Free Analysis |
|
|
INDP Important Levels Intraday
| RESISTANCE | 2.18 |
| RESISTANCE | 2.13 |
| RESISTANCE | 2.09 |
| RESISTANCE | 2.06 |
| SUPPORT | 1.96 |
| SUPPORT | 1.93 |
| SUPPORT | 1.89 |
| SUPPORT | 1.84 |
INDP Forecast May 2024
| 4th UP Forecast | 7.48 |
| 3rd UP Forecast | 5.73 |
| 2nd UP Forecast | 4.64 |
| 1st UP Forecast | 3.56 |
| 1st DOWN Forecast | 0.46 |
| 2nd DOWN Forecast | -0.62 |
| 3rd DOWN Forecast | -1.71 |
| 4th DOWN Forecast | -3.46 |
INDP Weekly Forecast
| 4th UP Forecast | 4.17 |
| 3rd UP Forecast | 3.48 |
| 2nd UP Forecast | 3.05 |
| 1st UP Forecast | 2.62 |
| 1st DOWN Forecast | 1.40 |
| 2nd DOWN Forecast | 0.97 |
| 3rd DOWN Forecast | 0.54 |
| 4th DOWN Forecast | -0.15 |
INDP Forecast2024
| 4th UP Forecast | 13.28 |
| 3rd UP Forecast | 9.67 |
| 2nd UP Forecast | 7.43 |
| 1st UP Forecast | 5.2 |
| 1st DOWN Forecast | -1.18 |
| 2nd DOWN Forecast | -3.41 |
| 3rd DOWN Forecast | -5.65 |
| 4th DOWN Forecast | -9.26 |
Indaptus Therapeutics Inc. Common Stock ( NASDAQ USA Symbol : INDP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
INDP Business Profile
Indaptus Therapeutics, Inc., a pre-clinical stage biotech company, develops a patented anti-cancer and antiviral immunotherapy. It engages in developing a pre-clinical pipeline of therapeutic candidates intended to elicit anti-tumor and anti-viral responses, as well as cure diseases. The company's lead candidate is Decoy20 that is in pre-clinical stage to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma. It also develops a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company is headquartered in New York, New York. Address: Three Columbus Circle, New York, NY, United States, 10019
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service